News headlines about Impax Laboratories (NASDAQ:IPXL) have been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Impax Laboratories earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 46.7015455566811 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the media stories that may have impacted Accern’s rankings:
- SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Impax Laboratories, Inc. and Encourages Investors to Contact the Firm for Additional Information (finance.yahoo.com)
- $198.42 Million in Sales Expected for Impax Laboratories, Inc. (IPXL) This Quarter (americanbankingnews.com)
- Praesidium Investment Management Company Has Cut By $7.98 Million Its Progress Software (PRGS) Stake; Impax … – Hill Country Times (hillcountrytimes.com)
- SHAREHOLDER ALERT: Pomerantz LLP Investigates Claims That the Merger May Not Be in the Best Interest of … – PR Newswire (press release) (prnewswire.com)
- Impax Laboratories, Inc. (IPXL) Receives Average Recommendation of “Hold” from Brokerages (americanbankingnews.com)
Several analysts have issued reports on IPXL shares. Cantor Fitzgerald set a $20.00 target price on Impax Laboratories and gave the company a “buy” rating in a research report on Wednesday, August 9th. Cowen set a $20.00 target price on Impax Laboratories and gave the company a “hold” rating in a research report on Wednesday, August 9th. Canaccord Genuity set a $19.00 target price on Impax Laboratories and gave the company a “hold” rating in a research report on Wednesday, August 9th. Piper Jaffray Companies set a $17.00 target price on Impax Laboratories and gave the company a “hold” rating in a research report on Thursday, August 10th. Finally, Royal Bank Of Canada set a $17.00 target price on Impax Laboratories and gave the company a “hold” rating in a research report on Thursday, August 10th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $19.60.
Shares of Impax Laboratories (NASDAQ IPXL) opened at $16.60 on Wednesday. Impax Laboratories has a 52-week low of $7.75 and a 52-week high of $25.70. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.81 and a quick ratio of 1.32. The firm has a market capitalization of $1,248.81, a price-to-earnings ratio of 24.78, a PEG ratio of 1.07 and a beta of 0.94.
Impax Laboratories (NASDAQ:IPXL) last issued its quarterly earnings results on Thursday, November 9th. The specialty pharmaceutical company reported $0.23 EPS for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.03. Impax Laboratories had a positive return on equity of 9.06% and a negative net margin of 56.59%. The company had revenue of $206.40 million during the quarter, compared to analysts’ expectations of $208.38 million. During the same quarter in the previous year, the firm posted $0.37 EPS. The firm’s revenue was down 9.4% compared to the same quarter last year. research analysts expect that Impax Laboratories will post 0.63 earnings per share for the current fiscal year.
About Impax Laboratories
Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.
Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.